

# CITATION REPORT

List of articles citing

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

DOI: 10.1200/jco.2003.12.086

Journal of Clinical Oncology, 2003, 21, 607-14.

**Source:** <https://exaly.com/paper-pdf/35757116/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
421	Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. <b>2003</b> , 71, 327-33		20
420	Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study. <b>2003</b> , 71, 257-62		4
419	Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. <b>2003</b> , 98, 978-82		47
418	Recent publications in hematological oncology. <b>2003</b> , 21, 141-8		
417	Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients. <b>2003</b> , 57, 321-6		27
416	Hodgkin's lymphoma: the hazards of success. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 3388-90	2.2	14
415	Involved-field radiotherapy for advanced Hodgkin's lymphoma. <b>2003</b> , 348, 2396-406		255
414	Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. <b>2003</b> , 14, 1762-7		119
413	Clinicopathologic and molecular features of Hodgkin's lymphoma. <b>2003</b> , 2, 500-7		12
412	Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. <b>2003</b> , 2003, 225-47		115
411	Advanced Hodgkin's disease: ABVD is better, yet is not good enough!. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 583-5	2.2	13
410	Long term outcome in adolescents with Hodgkin's lymphoma: poor results using regimens designed for adults. <b>2004</b> , 45, 1579-85		15
409	RESPONSE: Re: Radiation Therapy in the Treatment of Hodgkin's Disease--Do You See What I See?. <b>2004</b> , 96, 236-237		
408	Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. <b>2004</b> , 15, 1798-804		55
407	Re: Radiation therapy in the treatment of Hodgkin's disease--do you see what I see?. <b>2004</b> , 96, 235-6; author reply 236-7		1
406	ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2835-41	2.2	266
405	Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. <b>2004</b> , 15, 276-82		41

404	How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1532-3	2.2	47
403	ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. <b>2004</b> , 125, 584-9		9
402	What is new in lymphoma?. <b>2004</b> , 54, 260-72		32
401	[Modern pharmacotherapy of Hodgkin disease]. <b>2004</b> , 45, 93-101		2
400	Second neoplasms in patients with chronic lymphocytic leukemia. <b>2004</b> , 5, 215-23		47
399	Therapeutic options in patients with lymphoma and severe liver dysfunction. <b>2004</b> , 79, 169-75		23
398	Lymphome de Hodgkin de l'adulte. <b>2004</b> , 1, 115-134		2
397	Progress in the prognosis of adult Hodgkin's lymphoma in the past 35 years through clinical trials in Argentina: a GATLA experience. <b>2004</b> , 5, 102-9		3
396	Trials in advanced Hodgkin's disease: more than 30 years experience of the British National Lymphoma Investigation. <b>2004</b> , 5, 174-83		8
395	The emerging role of reactive oxygen species in cancer therapy. <b>2004</b> , 40, 1934-40		180
394	Procarbazine in haematology: an old drug with a new life?. <b>2004</b> , 40, 1924-7		20
393	Part II: Hodgkin's lymphoma--diagnosis and treatment. <b>2004</b> , 5, 19-26		123
392	Lymphoma: present and future challenges. <b>2004</b> , 41, 26-31		10
391	Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. <b>2004</b> , 103, 58-66		21
390	Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. <b>2005</b> , 61, 175-84		10
389	Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). <b>2005</b> , 75, 90-7		50
388	Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?. <b>2005</b> , 75, 115-20		7
387	Current treatment strategies of the German Hodgkin Study Group (GHSg). <b>2005</b> , 75, 125-34		19

386	Behandlung fortgeschrittener Stadien des Hodgkin-Lymphoms. <b>2005</b> , 11, 942-947		
385	Behandlung mittlerer Stadien beim Hodgkin-Lymphom. <b>2005</b> , 11, 933-941		
384	Significado prognóstico dos graus histológicos do linfoma de Hodgkin do tipo esclerose nodular. <b>2005</b> , 41, 365		
383	Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5052-60	2.2	139
382	ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9198-207	2.2	144
381	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. <b>2005</b> , 16 Suppl 1, i54-5		15
380	Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. <b>2005</b> , 11, 2175-9		72
379	Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7614-20	2.2	216
378	Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4634-42	2.2	256
377	Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9208-18	2.2	115
376	A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSg) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). <b>2005</b> , 16, 124-31		129
375	Drug-induced respiratory disease in patients with hematological diseases. <b>2005</b> , 26, 458-81		28
374	State-of-the-art therapeutics: Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6400-8	2.2	189
373	The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: overweight which side?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9058-62	2.2	12
372	The case for randomized trials in cancer treatment: new is not always better. <b>2005</b> , 293, 1001-3		9
371	Evolving approaches to primary treatment of Hodgkin lymphoma. <b>2005</b> , 2005, 239-44		15
370	Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. <b>2005</b> , 28, 567-71		8
369	Hodgkin Lymphoma in adolescents. <b>2005</b> , 31, 339-60		19

368	Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. <b>2005</b> , 41, 998-1006	46
367	ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do?. <b>2005</b> , 6, 50-1	4
366	Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. <b>2006</b> , 47, 641-56	7
365	Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. <b>2006</b> , 47, 657-63	13
364	Management of Hodgkin lymphoma. <b>2006</b> , 81, 419-26	39
363	Historical Overview and Current State of Art in Diagnosis and Treatment of Hodgkin's and Non-Hodgkin's Lymphoma. <b>2006</b> , 1, 203-17	3
362	German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies. <b>2006</b> , 6, 458-68	7
361	High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease. <b>2006</b> , 12, 942-8	10
360	Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea. <b>2006</b> , 47, 455-65	5
359	Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <b>2006</b> , 107, 4636-42	42
358	Management of advanced stage Hodgkin lymphoma. <b>2006</b> , 4, 241-7	9
357	The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. <b>2006</b> , 20, 2162-8	41
356	Hodgkin's lymphoma. <b>2006</b> , 30, 107-58	6
355	First-line treatment of Hodgkin's lymphoma. <b>2006</b> , 1, 51-9	2
354	Anthracycline-induced cardiotoxicity in adult hematologic malignancies. <b>2006</b> , 33, S22-7	19
353	A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. <b>2006</b> , 11, 25-9	17
352	Current strategies and new approaches in the treatment of Hodgkin's lymphoma. <b>2006</b> , 73, 126-40	17
351	Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. <b>2006</b> , 98, 215-8	67

350	Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?. <b>2006</b> , 24, 461-5		7
349	The impact of treatment on the risk of second malignancy after Hodgkin's disease. <b>2006</b> , 17, 1727-9		4
348	Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?. <b>2006</b> , 24, 713-7		18
347	Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 544-8	2.2	26
346	The cancer and leukemia group B lymphoma committee. <b>2006</b> , 12, 3572s-5s		1
345	MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. <b>2006</b> , 12, 529-35		11
344	Hodgkin's Lymphoma: Diagnosis and Treatment. <b>2006</b> , 476-499		
343	The epidemiology of second primary cancers. <b>2006</b> , 15, 2020-6		202
342	American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3991-4008	2.2	589
341	ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. <b>2007</b> , 18, 376-80		52
340	Risk, cure and complications in advanced hodgkin disease. <b>2007</b> , 2007, 197-203		15
339	Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies. <b>2007</b> , 18 Suppl 9, ix71-9		22
338	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3746-52	2.2	667
337	Hodgkin's disease: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2007</b> , 18 Suppl 2, ii53-4		3
336	Salvage therapy in Hodgkin's lymphoma. <b>2007</b> , 12, 156-67		23
335	FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity. <b>2007</b> , 92, e120-1		36
334	Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. <b>2007</b> , 109, 905-9		105
333	Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?. <b>2007</b> , 37, 37-41		4

332	The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma. <b>2007</b> , 37, 49-56	3
331	Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. <b>2007</b> , 18, 1376-81	44
330	High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. <b>2007</b> , 48, 1728-35	8
329	Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. <b>2007</b> , 18, 1071-9	191
328	Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?. <b>2007</b> , 21, 881-96	3
327	New strategies for the treatment of advanced-stage Hodgkin's lymphoma. <b>2007</b> , 21, 897-914	18
326	Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. <b>2007</b> , 8 Suppl 2, S63-6	5
325	New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. <b>2007</b> , 21, 825-40	35
324	Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. <b>2007</b> , 67, 19-30	54
323	G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <b>2007</b> , 137, 545-52	61
322	Deglycosylated bleomycin induces apoptosis in lymphoma cell via c-jun NH2-terminal kinase but not reactive oxygen species. <b>2007</b> , 74, 1445-55	8
321	Radiotherapy of hodgkin lymphoma: indications, new fields, and techniques. <b>2007</b> , 17, 206-22	33
320	The contribution of Gianni Bonadonna to the history of chemotherapy. <b>2007</b> , 60, 309-12	6
319	Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. <b>2007</b> , 8, 352-74	13
318	The role of radiation therapy in patients with Hodgkin's lymphoma. <b>2007</b> , 2, 151-60	3
317	Is BEACOPP better than ABVD?. <b>2007</b> , 2, 161-6	7
316	Lymphome de Hodgkin: traitement des stades localis�sus-diaphragmatiques. <b>2008</b> , 10, 303-306	0
315	Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation. <b>2008</b> , 112, 846-55	2

314	Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. <b>2008</b> , 70, 161-5	28
313	Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. <b>2008</b> , 70, 161-5	19
312	Deglycosylated bleomycin triggers apoptosis in laryngeal carcinoma cells in a caspase and reactive oxygen species independent manner. <b>2008</b> , 37, 352-7	6
311	British HIV Association guidelines for HIV-associated malignancies 2008. <b>2008</b> , 9, 336-88	108
310	Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. <b>2008</b> , 142, 69-73	100
309	Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. <b>2008</b> , 35, 470-83	5
308	Treatment of Hodgkin lymphoma: the past, present, and future. <b>2008</b> , 5, 543-56	75
307	Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. <b>2008</b> , 49, 1530-6	9
306	PET imaging for response assessment in lymphoma: potential and limitations. <b>2008</b> , 46, 225-41, viii	33
305	Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. <b>2008</b> , 19, 1915-20	7
304	Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma. <b>2008</b> , 14, 1759-66	24
303	Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. <b>2008</b> , 19, 1759-64	31
302	[malignant lymphoma. Physiopathology and treatment. 1. Hodgkin's lymphoma]. <b>2008</b> , 97, 1568-80	
301	Poor outcome in adolescents with high-risk Hodgkin lymphoma. <b>2008</b> , 33, 145-51	1
300	Hodgkin lymphoma in older patients. <b>2009</b> , 5, 395-407	
299	ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 805-11	2.2 206
298	Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. <b>2009</b> , 15, 4365-73	49
297	Secondary breast cancer in Hodgkin's lymphoma survivors. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4229-31.2	21

296	Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4548-54	2.2	351
295	Gemcitabine and vinorelbine therapy for patients with Hodgkin lymphoma. <b>2009</b> , 3, 525-532		
294	Standard therapy of advanced Hodgkin lymphoma. <b>2009</b> , 497-506		54
293	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. <b>2009</b> , 94, 550-65		59
292	Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5390-6	2.2	139
291	Salvage therapy in Hodgkin's lymphoma. <b>2009</b> , 14, 425-32		26
290	Does radiotherapy still have a place in Hodgkin lymphoma?. <b>2009</b> , 4, 117-24		5
289	Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. <b>2009</b> , 88, 633-7		4
288	The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. <b>2009</b> , 88, 855-61		8
287	Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?. <b>2009</b> , 88, 1107-12		3
286	Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. <b>2009</b> , 146, 158-63		114
285	FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease. <b>2009</b> , 70, 499-506		8
284	Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunction. <b>2009</b> , 9, 167-70		8
283	Role of radiation therapy in Hodgkin's lymphoma. <b>2009</b> , 15, 155-60		15
282	Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma. <b>2009</b> , 15, 117-23		24
281	Combined modality treatment of Hodgkin's lymphoma. <b>2009</b> , 15, 143-9		12
280	Role of chemotherapy in Hodgkin's lymphoma. <b>2009</b> , 15, 150-4		17
279	Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. <b>2010</b> , 95, 1496-502		14

278	Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. <b>2010</b> , 116, 418-27	123
277	An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. <b>2010</b> , 8, 347-52	21
276	Phase II study of ABVD therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). <b>2010</b> , 92, 713-24	15
275	Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?. <b>2010</b> , 5, 148-56	8
274	Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma?. <b>2010</b> , 5, 229-38	4
273	Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. <b>2010</b> , 20, 30-44	60
272	Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. <b>2010</b> , 3, 27	12
271	Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy. <b>2010</b> , 32, 527-31	7
270	Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. <b>2010</b> , 79, 1544-52	27
269	Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review. <b>2010</b> , 76, 1166-70	2
268	Lymphome de Hodgkin de l'adulte. <b>2010</b> , 16, 39-44	
267	Advanced Hodgkin's lymphoma: results in 216 patients treated with ABVD in Brazil. <b>2010</b> , 32, 303-307	2
266	Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). <b>2010</b> , 21, 568-573	11
265	What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e8	2.2 32
264	Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. <b>2010</b> , 21, 574-581	21
263	Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3352-9 <sup>2.2</sup>	61
262	Hodgkin lymphoma in a thymic cyst: report of a case with multiple secondary neoplasms. <b>2010</b> , 2010, 795037	1
261	Re: Late effects from radiation therapy: the hits just keep on coming. <b>2010</b> , 102, 576-7; author reply 577-8	3

260	The past: what we have learned in the last decade. <b>2010</b> , 2010, 101-7		18
259	Hodgkin's lymphoma therapy: past, present, and future. <b>2010</b> , 11, 2891-906		25
258	Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). <b>2010</b> , 9, 14		11
257	Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. <b>2010</b> , 10, E22-5		13
256	Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study. <b>2010</b> , 10, 181-5		2
255	A decade of progress in lymphoma: advances and continuing challenges. <b>2010</b> , 10, 414-23		38
254	Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience. <b>2010</b> , 21, 2061-2068		55
253	Treatment of Hodgkin Lymphoma. <b>2010</b> , 367-389		
252	Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. <b>2010</b> , 21, 126-32		70
251	Human immunodeficiency and Hodgkin lymphoma. <b>2010</b> , 42, 131-9		17
250	Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. <b>2011</b> , 3, 26		15
249	Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> . <b>2011</b> , 29, 4881-90	2.2	146
248	Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. <b>2011</b> , 118, 4585-90		62
247	Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. <b>2011</b> , 11, 396-402		10
246	Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. <b>2011</b> , CD007941		26
245	Hodgkin Lymphoma. <b>2011</b> ,		3
244	Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. <b>2011</b> , 8, 311-325		2
243	Maladie de Hodgkin ou lymphome hodgkinien. <b>2011</b> , 6, 1-5		

242	Lymphome de Hodgkin de l'adulte. <b>2011</b> , 6, 1-17		1
241	Hodgkin lymphoma. <b>2011</b> , 9, 1020-58		35
240	Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. <b>2011</b> , 153, 191-8		18
239	Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. <b>2011</b> , 153, 358-63		27
238	Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. <b>2011</b> , 38, 1064-71		73
237	Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. <b>2011</b> , 90, 67-72		15
236	ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation. <b>2011</b> , 90, 971-3		3
235	Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. <b>2011</b> , 90, 803-8		28
234	Anticancer chemotherapeutic agents and testicular dysfunction. <b>2011</b> , 10, 81-87		6
233	Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. <b>2011</b> , 86, 170-9		26
232	Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management. <b>2011</b> , 86, 851-8		4
231	Liposomes for enhanced cytotoxic activity of bleomycin. <b>2011</b> , 72, 265-273		9
230	ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. <b>2011</b> , 365, 203-12		282
229	Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4227-33	2.2	38
228	Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma. <b>2011</b> , 2011, 258797		14
227	Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. <b>2011</b> , 2011, 656013		2
226	Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas. <b>2011</b> , 2011, 707542		11
225	Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. <b>2011</b> , 2011, 725219		70

224	The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future. <b>2011</b> , 2011, 865870		6
223	Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. <b>2011</b> , 2, 289-295		1
222	Optimal therapy of advanced Hodgkin lymphoma. <b>2011</b> , 2011, 310-6		17
221	Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!. <b>2011</b> , 8, 636-7		2
220	Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. <b>2012</b> , 138, 846-54		37
219	Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. <b>2012</b> , 17, 367-76		12
218	International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3383-8	2.2	127
217	The case for chemotherapy alone for limited-stage Hodgkin's lymphoma. <b>2012</b> , 17, 1011-3		1
216	Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. <b>2012</b> , 53, 2390-6		21
215	ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. <b>2012</b> , 366, 399-408		272
214	A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. <b>2012</b> , 53, 259-62		58
213	Toward risk-based breast cancer screening and prevention strategies for survivors of Hodgkin's lymphoma: one step closer?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2712-4	2.2	
212	Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin. <b>2012</b> , 6, 31-9		14
211	Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. <b>2012</b> , 17, 80-90		20
210	Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. <b>2012</b> , 379, 1791-9		446
209	Hodgkin's lymphoma in adults. <b>2012</b> , 380, 836-47		96
208	Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. <b>2012</b> , 87, 1096-103		31
207	Enfermedad o linfoma de Hodgkin. <b>2012</b> , 16, 1-5		

206	Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. <b>2012</b> , 53, 801-6	6
205	Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. <b>2012</b> , 53, 596-602	8
204	A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. <b>2012</b> , 208, 363-7	8
203	Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. <b>2012</b> , 18, 640-7	8
202	Treatment of newly diagnosed advanced stage Hodgkin lymphoma. <i>Blood Reviews</i> , <b>2012</b> , 26, 167-74	11.1 10
201	Matrix metalloproteinase-9 is consistently expressed in Hodgkin/Reed-Sternberg cells and has no impact on survival in patients with Epstein-Barr virus (EBV)-related and non-related Hodgkin lymphoma in Brazil. <b>2012</b> , 29, 2148-52	3
200	State of the Art Therapy of Advanced Hodgkin Lymphoma. <b>2012</b> ,	
199	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. <b>2012</b> , 119, 4123-8	60
198	State of the art in the treatment of Hodgkin lymphoma. <b>2012</b> , 9, 450-9	55
197	ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years. <b>2012</b> , 18, 675-80	2
196	A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. <b>2012</b> , 87, 32-6	26
195	Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. <b>2012</b> , 91, 215-21	12
194	Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). <b>2012</b> , 91, 223-33	8
193	Actualit� th�rapeutiques dans les lymphomes. <b>2013</b> ,	
192	Progress in the initial management of Hodgkin's Lymphoma. <b>2013</b> , 49, 12-8	2
191	Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. <b>2013</b> , 14, 943-52	132
190	Therapeutic effects of thalidomide in hematologic disorders: a review. <b>2013</b> , 7, 290-300	9
189	TEP/TDM au FDG et toxicit� pulmonaire de la blomycine: propos d'un cas clinique. <b>2013</b> , 37, 124-126	0

188	Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. <b>2013</b> , 50, 4-14		19
187	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <b>2013</b> , 14, 1348-56		212
186	Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705). <b>2013</b> , 54, 46-52		5
185	MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <b>2013</b> , 162, 336-47		32
184	Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 456-60	2.2	144
183	Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, and Gastrointestinal Tract. <b>2013</b> , 785-794		
182	Modern management of lymphocyte-predominant Hodgkin lymphoma. <b>2013</b> , 161, 316-29		7
181	Immunologic pathomechanism of Hodgkin's lymphoma. <b>2013</b> , 41, 995-1004		11
180	Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2819-24	2.2	48
179	Hodgkin lymphoma. <b>2013</b> , 41, 290-294		
178	Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 684-91	2.2	204
177	Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma. <b>2013</b> , 13, 1013-27		2
176	Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. <b>2013</b> , 54, 1706-12		3
175	Revisiting bleomycin from pathophysiology to safe clinical use. <b>2013</b> , 87, 90-100		68
174	Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?. <b>2013</b> , 2013, 406-13		8
173	Refractory Hodgkin lymphoma. <b>2013</b> , 25, 463-9		9
172	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. <b>2013</b> , 109, 2560-5		6
171	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. <b>2013</b> , 98, 611-4		81

170	MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients. <b>2013</b> , 8, e64716		21
169	Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese. <b>2014</b> , 10, 498-504		2
168	Immunostaining and time-lapse analysis of vinblastine-induced paracrystal formation in human A549 cells. <b>2014</b> , 8, 2387-2392		4
167	Isolated CNS Hodgkin's lymphoma: implications for tissue diagnosis. <b>2014</b> , 3, 383-7		6
166	[News in hodgkin lymphoma therapy]. <b>2014</b> , 101, 68-74		
165	Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis. <b>2014</b> , 55, 56-62		2
164	Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures. <b>2014</b> , 272, 262-74		34
163	A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. <b>2014</b> , 166, 118-29		7
162	Guidelines for the first line management of classical Hodgkin lymphoma. <b>2014</b> , 166, 34-49		52
161	Treatment of Hodgkin lymphoma: a 50-year perspective. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 163-8	2.2	104
160	Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: a retrospective analysis. <b>2014</b> , 34, 260-264		2
159	Which Hodgkin's patients in the Unites States should be treated with BEACOPP?. <b>2014</b> , 9, 222-6		1
158	Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. <b>2014</b> , 89, 771-9		24
157	How I treat advanced classical Hodgkin lymphoma. <b>2015</b> , 125, 1717-23		18
156	Hodgkin lymphoma, version 2.2015. <b>2015</b> , 13, 554-86		26
155	Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults. <b>2015</b> , 5, 97-102		4
154	The GHSG Approach to Treating Hodgkin's Lymphoma. <b>2015</b> , 10, 256-65		3
153	Hodgkin Lymphoma. <b>2015</b> ,		11

152	Principles of Radiation Therapy for Hodgkin Lymphoma. <b>2015</b> , 157-176		0
151	Principles of Chemotherapy in Hodgkin Lymphoma. <b>2015</b> , 177-199		
150	Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. <b>2015</b> , 107,		29
149	Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. <b>2015</b> , 26, 1170-1174		31
148	Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. <b>2015</b> , 125, 1693-702		34
147	Risk-adapted strategies for the treatment of Hodgkin lymphoma. <b>2015</b> , 14, 1519-30		2
146	Hodgkin Lymphoma: Diagnosis and Treatment. <b>2015</b> , 90, 1574-83		81
145	Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma. <b>2015</b> , 11, 2149-57		2
144	Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy. <b>2015</b> , 45, 137-45		7
143	Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. <b>2015</b> , 56, 2013-8		3
142	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <b>2015</b> , 56, 703-10		25
141	Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience. <b>2016</b> , 32, 1408-1413		
140	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2493-500	2.2	39
139	Prognostic factors in Hodgkin lymphoma. <b>2016</b> , 53, 155-64		26
138	Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score IB, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2028-35	2.2	88
137	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2020-7	2.2	184
136	Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome. <b>2016</b> , 24, 383-91		5
135	Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues. <b>2016</b> , 24, 6094-6101		6

134	Lymphoma in Adolescents and Young Adults. <b>2016</b> , 43, 101-14	5
133	Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. <b>2016</b> , 91, 109-12	15
132	Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. <b>2016</b> , 91, 434-42	65
131	Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. <b>2016</b> , 104, 236-44	14
130	Nodular lymphocyte-predominant Hodgkin lymphoma. <b>2016</b> , 53, 190-202	19
129	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <b>2016</b> , 374, 2419-29	428
128	Treatment of advanced-stage Hodgkin lymphoma. <b>2016</b> , 53, 171-9	20
127	Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. <b>2016</b> , 57, 1865-75	1
126	Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. <b>2016</b> , 16, 347-64	3
125	Hodgkin's Lymphoma. <b>2016</b> , 1506-1523.e5	
124	Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study. <b>2016</b> , 135, 29-36	9
123	Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China. <b>2017</b> , 17, 274-282	2
122	Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. <b>2017</b> , 58, 2607-2614	10
121	ABVD or BEACOPP along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. <b>2017</b> , 81, 45-55	20
120	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <b>2017</b> , 15, 608-638	63
119	Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia. <b>2017</b> , 40, 288-292	7
118	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. <b>2017</b> , 9, 423-433	6
117	Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. <b>2017</b> , 97, 1066-1076	15

116	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <b>2017</b> , 109,	22
115	Hodgkin's lymphoma in developing countries: can we go further?. <b>2017</b> , 39, 299-300	
114	Classic Hodgkin lymphoma in pelvis: A case report highlights diagnosis and treatment challenges. <b>2017</b> , 96, e8196	4
113	The combination of Bleomycin with TRAIL agonists or PKC inhibitors sensitizes solid tumor cells to BLM-mediated apoptosis: new strategies to overcome chemotherapy resistance of tumors. <b>2017</b> , 26, 2105-2111	1
112	Survival Pattern of Hodgkin Lymphoma Patients in the Last 25 Years in Lebanon. <b>2017</b> , 17S, S88-S91	
111	Optimizing therapy in advanced-stage Hodgkin lymphoma. <b>2018</b> , 131, 1679-1688	16
110	Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma. <b>2018</b> , 378, 1560-1561	9
109	Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. <b>2018</b> , 93, 704-715	70
108	Hodgkin Lymphoma in Adults. <b>2018</b> , 434-443	
107	PET-adapted therapy for advanced Hodgkin lymphoma - systematic review. <b>2018</b> , 57, 765-772	8
106	Precision Molecular Pathology of Hodgkin Lymphoma. <b>2018</b> ,	1
105	Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging. <b>2018</b> , 18, 145-151	3
104	Chimeric antigen receptor T-cell therapies for lymphoma. <b>2018</b> , 15, 31-46	291
103	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 454-462	2.2 125
102	Acute liver failure secondary to ABVD use. <b>2018</b> , 2018,	1
101	Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis. <b>2018</b> , 10, 6017-6028	0
100	Microgravity induces autophagy via mitochondrial dysfunction in human Hodgkin's lymphoma cells. <b>2018</b> , 8, 14646	18
99	Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity. <b>2018</b> , 24, 223-229	1

98	Letter comments on a published article in the New England Journal of Medicine. <b>2018</b> , 104, 250-251		
97	Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era. <b>2018</b> , 8, 13-20		2
96	Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. <b>2018</b> , 11, 503-511		3
95	High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma. <b>2018</b> , 104, 471-475		1
94	Hodgkin Lymphoma: Clinical Manifestations, Staging, and Therapy. <b>2018</b> , 1212-1229		1
93	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <b>2019</b> , 134, 1238-1246		50
92	[Treatment of Hodgkin lymphoma. Analysis of 915 patients]. <b>2019</b> , 147, 437-443		1
91	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1997-2007	2.2	110
90	Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. <b>2019</b> , 12, 255-264		3
89	Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence. <b>2019</b> , 5, 1-13		2
88	Cancer and AIDS. <b>2019</b> ,		
87	The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. <b>2019</b> , 60, 927-933		13
86	Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma - A Real-world Analysis. <b>2019</b> , 19, e71-e79		3
85	Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. <b>2020</b> , 61, 298-308		4
84	Therapy Response Imaging in Oncology. <b>2020</b> ,		
83	Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation. <b>2020</b> , 6, 1093-1102		2
82	Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review. <b>2020</b> , 13, 907-922		2
81	Radiotherapy for patients with stage IV classical Hodgkin lymphoma: a propensity-matched analysis of the surveillance, epidemiology, and end results database. <b>2020</b> , 21, 832-840		

80	Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. <b>2020</b> , 95, 978-989		21
79	Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma. <b>2020</b> , 37, 1755-1761		2
78	PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma. <b>2020</b> , 11, 2040620720914490		2
77	Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. <b>2020</b> , 11, 2040620720902911		8
76	First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. <b>2020</b> , 190, 222-235		4
75	Drug-Related Carcinogenesis: Risk Factors and Approaches for Its Prevention. <b>2020</b> , 85, S79-S107		5
74	Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 662-668	2.2	1
73	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <b>2020</b> , 135, 735-742		54
72	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. <b>2021</b> , 62, 1057-1065		3
71	Classical Hodgkin lymphoma. <b>2021</b> , 398, 1518-1527		7
70	Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 346-360	2.2	2
69	Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel. <b>2021</b> , 96, 1087-1100		0
68	Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a population-based competing risk analysis. <b>2021</b> , 21, 955		0
67	Synchronous occurrence of Hurthle cell carcinoma with Hodgkin's lymphoma; the first reported case with literature review. <b>2021</b> , 69, 102750		1
66	Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience. <b>2021</b> , 57,		
65	Management of advanced stage Hodgkin's lymphoma. <b>2006</b> , 131, 333-52		2
64	Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma. <b>2011</b> , 7-20		0
63	Treatment of Advanced Stage Hodgkin Lymphoma. <b>2011</b> , 191-202		1

62	Prognostic Factors. <b>2011</b> , 97-115	1
61	Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy. <b>2011</b> , 34, 499-505	6
60	Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. <b>2007</b> , 3, 213-24	22
59	Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study. <b>2015</b> , 61, 88-91	6
58	Hodgkin Lymphoma: A Special Microenvironment. <b>2021</b> , 10,	1
57	Principles, Indications, and Techniques of Radiation Therapy of Lymphomas. <b>2006</b> , 203-224	1
56	Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease. <b>2007</b> , 42, 335	
55	Hodgkin's Lymphoma. <b>2008</b> , 2353-2369	1
54	[Autologous stem cell transplantation in the treatment of Hodgkin's disease]. <b>2009</b> , 66, 571-6	
53	Allogeneic Transplantation for Hodgkin's Lymphoma. <b>2010</b> , 75-88	
52	Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma. <b>2011</b> , 21-29	
51	Principles of Chemotherapy in Hodgkin Lymphoma. <b>2011</b> , 141-161	1
50	Principles of Radiation Techniques in Hodgkin Lymphoma. <b>2011</b> , 117-139	
49	Treatment of Early Unfavorable HL. <b>2011</b> , 183-190	
48	Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma. <b>2011</b> , 31-44	
47	Hodgkin Lymphoma. 639-654	
46	Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. <b>2011</b> , 33, 432-8	1
45	Hodgkin Lymphoma. 296-314	1

- 44 Hodgkin's Lymphoma. **2012**, 1527-1543 1
- 43 Lymphomas. **2013**, 153-187
- 42 Lymphome de Hodgkin : traitement de première ligne des stades avancés. **2013**, 31-41
- 41 Traitement des patients réfractaires primaires ou en première rechute de lymphomes hodgkiniens. **2013**, 43-54
- 40 Traitement des lymphomes de Hodgkin localisés. **2013**, 3-30
- 39 Lymphomes : principes thérapeutiques et imagerie post-thérapeutique. **2014**, 265-298
- 38 Treatment of Early Unfavorable HL. **2015**, 221-234
- 37 Treatment of Advanced-Stage Hodgkin Lymphoma. **2015**, 235-250
- 36 Prognostic Factors. **2015**, 131-155 1
- 35 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2016**, 1-42
- 34 Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, and Gastrointestinal Tract. **2016**, 1-15
- 33 ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy. **2016**, 37, 106-11
- 32 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2017**, 353-393
- 31 Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, and Gastrointestinal Tract. **2017**, 1513-1527
- 30 Treatment and Prognosis. **2018**, 197-219
- 29 Therapy of Cancer and Retroviral Diseases. **2019**, 65-158 1
- 28 Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma. **2020**, 60, 78-86 2
- 27 Therapy Response Imaging in Lymphoma and Hematologic Malignancies. **2020**, 177-200

- 26 Treatment of Advanced-Stage Hodgkin Lymphoma. **2020**, 249-264
- 25 Principles of Chemotherapy in Hodgkin Lymphoma. **2020**, 199-218
- 24 Prognostic Factors. **2020**, 145-169
- 23 An Evidence-Based Approach to the Management of Hodgkin Lymphoma. **2006**, 1240-1255
- 22 Management of early stage Hodgkin's lymphoma. **2006**, 131, 317-32
- 21 Hodgkin-Lymphom. 318-341
- 20 Treatment of Pediatric Hodgkin Lymphoma. **2007**, 35-66
- 19 Hodgkin's lymphoma. *Clinical Evidence*, **2009**, 2009,
- 18 Oncologists' Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG). *Asian Pacific Journal of Cancer Prevention*, **2017**, 18, 3149-3155 1.7
- 17 Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma. *Frontiers in Pharmacology*, **2021**, 12, 694545 5.6 ○
- 16 Using interim positron emission tomography as a predictor for relapse-free survival in Hodgkin lymphoma: Experience from a single Institution. *Journal of Cancer Research and Practice*, **2021**, 8, 134 0.4 ○
- 15 Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi.. *Cancers*, **2022**, 14, 6.6 ○
- 14 A review of pathobiology and therapies for classic Hodgkin lymphoma.. *Blood Reviews*, **2022**, 100949 11.1 ○
- 13 Real-world outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective.. *Transplantation and Cellular Therapy*, **2021**, 1
- 12 Hodgkin lymphoma: epidemiology, diagnosis, and treatment. 367-403
- 11 Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, Gastrointestinal Tract, and Central Nervous System. **2022**, 1-20
- 10 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2022**, 1-45
- 9 Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, Gastrointestinal Tract, and Central Nervous System. **2022**, 1755-1774 ○

- 8 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2022**, 431-474
- 7 Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.
- 6 Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
- 5 Is the integration of lymphocyte/monocyte ratio and international prognostic score effective in predicting prognosis for hodgkin's lymphoma in the modern era? A prospective cohort study. **2022**, 13, 201
- 4 Hodgkin Lymphoma. 1-12
- 3 Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era. **2022**, 14, 5390
- 2 Advances in the treatment of Hodgkin lymphoma: Current and future approaches. 13,
- 1 Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population.